000275594 001__ 275594
000275594 005__ 20240229154943.0
000275594 0247_ $$2doi$$a10.3389/fonc.2023.1167082
000275594 0247_ $$2pmid$$apmid:37091147
000275594 0247_ $$2pmc$$apmc:PMC10114612
000275594 0247_ $$2altmetric$$aaltmetric:145929415
000275594 037__ $$aDKFZ-2023-00805
000275594 041__ $$aEnglish
000275594 082__ $$a610
000275594 1001_ $$aJones, Chris$$b0
000275594 245__ $$aEvaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks.
000275594 260__ $$aLausanne$$bFrontiers Media$$c2023
000275594 3367_ $$2DRIVER$$aarticle
000275594 3367_ $$2DataCite$$aOutput Types/Journal article
000275594 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1682340852_14651
000275594 3367_ $$2BibTeX$$aARTICLE
000275594 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275594 3367_ $$00$$2EndNote$$aJournal Article
000275594 520__ $$aClinical outcomes for many childhood brain tumours remain poor, despite our increasing understanding of the underlying disease biology. Advances in molecular diagnostics have refined our ability to classify tumour types and subtypes, and efforts are underway across multiple international paediatric neuro-oncology consortia to take novel biological insights in the worst prognosis entities into innovative clinical trials. Whilst for the first time we are designing such studies on the basis of disease-specific biological data, the levels of preclincial evidence in appropriate model systems on which these trials are initiated is still widely variable. We have considered these issues between CONNECT, PNOC and ITCC-Brain, and developed a framework in which we can assess novel concepts being brought forward for possible clinical translation. Whilst not intended to be proscriptive for every possible circumstance, these criteria provide a basis for self-assessment of evidence by laboratory scientists, and a platform for discussion and rational decision-making prior to moving forward clinically.
000275594 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000275594 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275594 650_7 $$2Other$$aCNS
000275594 650_7 $$2Other$$ain vitro
000275594 650_7 $$2Other$$ain vivo
000275594 650_7 $$2Other$$amodels
000275594 650_7 $$2Other$$apediatric
000275594 650_7 $$2Other$$apreclinical
000275594 650_7 $$2Other$$atranslational
000275594 7001_ $$aStraathof, Karin$$b1
000275594 7001_ $$aFouladi, Maryam$$b2
000275594 7001_ $$aHargrave, Darren$$b3
000275594 7001_ $$aPrados, Michael$$b4
000275594 7001_ $$aResnick, Adam$$b5
000275594 7001_ $$aDoz, Francois$$b6
000275594 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b7$$udkfz
000275594 7001_ $$aMueller, Sabine$$b8
000275594 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2023.1167082$$gVol. 13, p. 1167082$$p1167082$$tFrontiers in oncology$$v13$$x2234-943X$$y2023
000275594 909CO $$ooai:inrepo02.dkfz.de:275594$$pVDB
000275594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000275594 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000275594 9141_ $$y2023
000275594 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000275594 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000275594 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-11T13:25:45Z
000275594 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000275594 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000275594 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-08
000275594 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-08
000275594 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T13:25:45Z
000275594 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000275594 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000275594 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x0
000275594 980__ $$ajournal
000275594 980__ $$aVDB
000275594 980__ $$aI:(DE-He78)B360-20160331
000275594 980__ $$aUNRESTRICTED